Product image of Lenalidomida Zentiva (Lenalidomide) supplied by GNH India

Lenalidomida Zentiva

Active Ingredient:
Lenalidomide
Origin:
EU

Lenalidomida Zentiva (Lenalidomide)

Lenalidomide, the active ingredient in Lenalidomida Zentiva, is an immunomodulatory drug presented as an oral formulation for oral use. It is indicated for the treatment of multiple myeloma, myelodysplastic syndromes and mantle‑cell lymphoma in adult patients for whom it is clinically appropriate.

GNH India supplies Lenalidomida Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Manufacturer / TM Owner

Zentiva, K.S.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Lenalidomida Zentiva is an immunomodulatory agent used in hematologic malignancies and related disorders.

  • Multiple Myeloma: improves disease control and prolongs progression‑free survival.
  • Myelodysplastic Syndromes: reduces transfusion dependence and delays transformation to acute leukemia.
  • Mantle Cell Lymphoma: contributes to tumor reduction and extends overall survival.

How It Works

  • Lenalidomide binds to the cereblon component of the CRL4 E3 ubiquitin ligase complex, promoting ubiquitination and proteasomal degradation of transcription factors Ikaros and Aiolos. This leads to modulation of the immune microenvironment, inhibition of angiogenesis, and direct anti‑myeloma activity through apoptosis and cell‑cycle arrest.

Side Effects

Lenalidomida Zentiva may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

  • Neutropenia: reduced neutrophil count increasing infection risk.
  • Thrombocytopenia: lowered platelet levels causing bleeding tendency.
  • Fatigue: persistent tiredness affecting daily activities.
  • Diarrhea: loose stools that may lead to dehydration.
  • Constipation: difficulty passing stools.
  • Rash: mild skin irritation or erythema.

Serious or Rare Side Effects

  • Venous thromboembolism: blood clots in deep veins or lungs.
  • Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
  • Secondary primary malignancies: emergence of new cancers.
  • Hepatic failure: significant liver enzyme elevation or dysfunction.
  • Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances.

Precautions & Warnings

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor laboratory parameters regularly.

  • Pregnancy: contraindicated (Category X); ensure effective contraception.
  • Thrombosis risk: assess need for prophylactic anticoagulation.
  • Hematologic monitoring: perform complete blood counts weekly initially.
  • Renal impairment: adjust dose based on creatinine clearance.
  • Hepatic dysfunction: monitor liver enzymes and adjust as needed.
  • Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Lenalidomida Zentiva can interact with several drug classes; some combinations should be avoided while others require close monitoring.

Major Interactions (Avoid)

  • Strong CYP3A4 inducers (e.g., rifampin): may reduce lenalidomide exposure.
  • Thalidomide or other IMiDs: increased risk of overlapping toxicities.
  • Live vaccines: potential for reduced vaccine efficacy and infection.

Moderate Interactions (Monitor Closely)

  • Anticoagulants (warfarin): may enhance bleeding risk; monitor INR.
  • NSAIDs: increase risk of renal impairment; assess renal function.
  • Digoxin: possible alteration of serum levels; check concentrations regularly.

Frequently Asked Questions

Lenalidomida Zentiva is prescribed for adult patients with multiple myeloma, myelodysplastic syndromes, and mantle‑cell lymphoma. It is used when clinicians determine that an immunomodulatory approach is appropriate to control disease progression, reduce transfusion needs, or improve survival outcomes.

Lenalidomide binds to cereblon, a component of the CRL4 E3 ubiquitin ligase complex, leading to the degradation of transcription factors Ikaros and Aiolos. This action modifies the immune response, inhibits new blood‑vessel formation, and triggers apoptosis of malignant plasma cells, thereby exerting anti‑myeloma activity.

The specific dose of Lenalidomida Zentiva is individualized by the prescribing physician based on the patient’s diagnosis, disease stage, renal function, and prior therapies. Only a qualified healthcare professional can determine the appropriate regimen.

Lenalidomida Zentiva is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy due to a high risk of fetal harm. It is also not recommended while breastfeeding because it may be excreted in milk and affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Lenalidomida Zentiva belongs to the immunomodulatory drug (IMiD) class, similar to thalidomide and pomalidomide. Compared with thalidomide, lenalidomide generally shows a more favorable safety profile, especially regarding peripheral neuropathy, while maintaining comparable anti‑myeloma efficacy. Pomalidomide may be used after lenalidomide failure, offering a different potency and side‑effect spectrum.

Store Lenalidomida Zentiva at ambient temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture, heat, and direct sunlight. Do not store in a refrigerator or freezer unless specifically instructed by the supplier.

Lenalidomida Zentiva is taken orally, usually once daily, with or without food as directed by the prescriber. The tablets should be swallowed whole with a glass of water and not crushed or chewed unless the prescribing information explicitly permits it.

Serious risks include venous thromboembolism, severe cutaneous reactions such as Stevens‑Johnson syndrome, secondary primary malignancies, and significant liver toxicity. Patients should be educated to report symptoms like unexplained swelling, rash, jaundice, or persistent fever promptly to their healthcare provider.

Lenalidomida Zentiva should not be used by pregnant women, individuals with known hypersensitivity to lenalidomide or its excipients, and patients with severe renal impairment without dose adjustment. Caution is also advised for those with uncontrolled infections or active hepatitis.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Lenalidomide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT